Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity

dc.contributor
Institut Català de la Salut
dc.contributor
[Marin I, Caballe A] Institute for Research in Biomedicine (IRB), Barcelona Institute of Science and Technology, Barcelona, Spain. [Boix O, Garcia-Garijo A, Garralda E, Abad M, Gros A] Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sirois I] CHU Sainte-Justine Research Center, Montréal, Québec, Canada. [Zarzuela E] Spanish National Cancer Research Center, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Marin, Ines
dc.contributor.author
Boix Sanchez, Olga
dc.contributor.author
Garcia Garijo, Andrea
dc.contributor.author
Sirois, Isabelle
dc.contributor.author
Caballe, Adria
dc.contributor.author
Zarzuela, Eduardo
dc.contributor.author
Garralda Cabanas, Elena
dc.contributor.author
Gros Vidal, Alena
dc.contributor.author
Abad, Maria
dc.date.accessioned
2025-10-25T05:37:28Z
dc.date.available
2025-10-25T05:37:28Z
dc.date.issued
2023-03-14T10:53:35Z
dc.date.issued
2023-03-14T10:53:35Z
dc.date.issued
2023-02-06
dc.identifier
Marin I, Boix O, Garcia-Garijo A, Sirois I, Caballe A, Zarzuela E, et al. Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity. Cancer Discov. 2023 Feb 6;13(2):410–31.
dc.identifier
2159-8290
dc.identifier
https://hdl.handle.net/11351/9164
dc.identifier
10.1158/2159-8290.CD-22-0523
dc.identifier
36302218
dc.identifier
000928218100001
dc.identifier.uri
http://hdl.handle.net/11351/9164
dc.description.abstract
Senescencia celular; Inmunidad antitumoral
dc.description.abstract
Senescència cel·lular; Immunitat antitumoral
dc.description.abstract
Cellular senescence; Antitumor immunity
dc.description.abstract
Cellular senescence is a stress response that activates innate immune cells, but little is known about its interplay with the adaptive immune system. Here, we show that senescent cells combine several features that render them highly efficient in activating dendritic cells (DC) and antigen-specific CD8 T cells. This includes the release of alarmins, activation of IFN signaling, enhanced MHC class I machinery, and presentation of senescence-associated self-peptides that can activate CD8 T cells. In the context of cancer, immunization with senescent cancer cells elicits strong antitumor protection mediated by DCs and CD8 T cells. Interestingly, this protection is superior to immunization with cancer cells undergoing immunogenic cell death. Finally, the induction of senescence in human primary cancer cells also augments their ability to activate autologous antigen-specific tumor-infiltrating CD8 lymphocytes. Our study indicates that senescent cancer cells can be exploited to develop efficient and protective CD8-dependent antitumor immune responses. Significance: Our study shows that senescent cells are endowed with a high immunogenic potential—superior to the gold standard of immunogenic cell death. We harness these properties of senescent cells to trigger efficient and protective CD8-dependent antitumor immune responses.
dc.description.abstract
We are grateful to Maria Isabel Muñoz for assistance with the animal protocols; to Kevin Kovalchik for help with data sharing; to Francesca Castoldi for help in total RNA extraction for B16F10 and IMR-90 cells; to Fredrik Fagerstrom-Billai, Susann Fält, Anastasios Damdimopoulos, and David Brodin at Bioinformatics and Expression Analysis Core Facility, Karolinska Institute (KI), for assistance in RNA-seq and analysis; to the IRB core facilities (Functional Genomics, Biostatistics/Bioinformatics and Histopathology); and to the PCB (Animal House) for general research support. I. Marin was the recipient of an FPI fellowship from the Spanish Ministry of Science (PRE2018-083381). O. Boix was the recipient of an FPI-AGAUR fellowship from the Generalitat de Catalunya. A. Garcia-Garijo was supported by a PERIS grant (SLT017/20/000131) from the Generalitat de Catalunya. J.A. López-Domínguez and M. Kovatcheva were supported by a fellowship from the Spanish Association Against Cancer (AECC). Work in the laboratory of E. Caron was funded by the Fonds de recherche du Québec – Santé (FRQS), the Cole Foundation, CHU Sainte-Justine, the Charles-Bruneau Foundation, the Canada Foundation for Innovation, the National Sciences and Engineering Research Council (#RGPIN-2020-05232), and the Canadian Institutes of Health Research (#174924). E. Garralda received funding from the Comprehensive Program of Cancer Immunotherapy and Immunology II (CAIMI-II) supported by the BBVA Foundation (grant 53/2021). The M. Abad lab received funding from the Spanish Ministry of Science and Innovation (RTI2018-102046-B-I00A and RTC-2017-6123-1) and the AECC (PRYCO211023SERR). M. Abad was the recipient of a Ramón y Cajal contract from the Spanish Ministry of Science and Innovation (RYC-2013-14747). A. Gros received funding from the Spanish Ministry of Science cofunded by the European Regional Development Fund (ERDF; RTC-2017-6123-1), from the Instituto de Salud Carlos III (MS15/00058), and from CAIMI-II (grant 53/2021) supported by the BBVA Foundation. The work in the laboratory of F. Pietrocola is supported by a KI Starting Grant, a Starting Grant from the Swedish Research Council (2019_02050_3), and grants from the Harald Jeanssons Foundation, the Loo and Hans Osterman Foundation, and Cancerfonden (21 1637 Pj). Work in the laboratory of M. Serrano was funded by the IRB and La Caixa Foundation, and by grants from the Spanish Ministry of Science cofunded by the European Regional Development Fund (SAF-2017-82613-R, RTC-2017-6123-1), the European Research Council (ERC-2014-AdG/669622), Secretaria d'Universitats i Recerca del Departament d'Empresa i Coneixement of Catalonia (Grup de Recerca consolidat 2017 SGR 282), and the AECC (PRYCO211023SERR). The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
dc.format
application/pdf
dc.language
eng
dc.publisher
American Association for Cancer Research
dc.relation
Cancer Discovery;13(2)
dc.relation
https://doi.org/10.1158/2159-8290.CD-22-0523
dc.rights
Attribution-NonCommercial-NoDerivatives 4.0 International
dc.rights
http://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.source
Scientia
dc.subject
Càncer
dc.subject
Immunització
dc.subject
Cèl·lules canceroses
dc.subject
PHENOMENA AND PROCESSES::Cell Physiological Phenomena::Cellular Senescence
dc.subject
DISEASES::Neoplasms
dc.subject
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Immunologic Techniques::Immunization
dc.subject
FENÓMENOS Y PROCESOS::fenómenos fisiológicos celulares::senescencia celular
dc.subject
ENFERMEDADES::neoplasias
dc.subject
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::técnicas inmunológicas::inmunización
dc.title
Cellular Senescence Is Immunogenic and Promotes Antitumor Immunity
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion


Fitxers en aquest element

FitxersGrandàriaFormatVisualització

No hi ha fitxers associats a aquest element.

Aquest element apareix en la col·lecció o col·leccions següent(s)